
News from Simply Wall St
Top Simply Wall St News

Eli Lilly · United StatesRecent results from Eli Lilly’s Phase 3 trial of orforglipron showed lower than expected weight loss, prompting speculation about increased competition in the obesity drug market.
This development has highlighted Viking Therapeutics as a potential player, as investors anticipate new data from its own obesity treatment trials later this year.
We’ll examine how the heightened anticipation for Viking’s upcoming clinical data could impact its broade…Read Article